Search Results

and pictilisib, and the dual PI3K/mTOR inhibitor gedatolisib. Initial trials of the AKT inhibitors provided a mixed signal of efficacy. In the phase II PAKT2 trial, capivasertib + paclitaxel improved median OS from 12.6 months to 19.1 months (HR, 0

. Phase III study of oral compared to intravenous topotecan as second-line therapy in small-cell lung cancer . J Clin Oncol 2007 ; 25 : 2086 – 2092 . 14. Dy GK Jett JR Geoffroy FJ . Topotecan and paclitaxel in previously treated patients

=.0067) but clinically modest 1.3-month progression-free survival benefit. 9 In the first-line setting of the BOLERO-1/TRIO 019 trial, trastuzumab/paclitaxel/everolimus did not improve progression-free survival overall. However, in the hormone receptor

to up-front therapy with carboplatin/paclitaxel or using bevacizumab as maintenance therapy; this disagreement is reflected as a category 3 recommendation. Most panel members believe that bevacizumab should not be added to up-front chemotherapy in

trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model . Clin Cancer Res 2005 ; 11 ( 19 Pt 1 ): 6966 – 6971 . 30. Eleutherakis-Papaiakovou V Bamias A Dimopoulos MA

ductal carcinoma who has triple-negative disease and no BRCA1 or BRCA2 mutation identified would be an anthracycline and taxane-based regimen, such as the regimen of dose-dense doxorubicin and cyclophosphamide followed by dose-dense paclitaxel

FOLFIRINOX [5-FU, leucovorin, irinotecan, and oxaliplatin] or gemcitabine) and the APACT study (NCT01964430; surgery followed by either gemcitabine/nanoparticle albumin-bound [nab]-paclitaxel or gemcitabine monotherapy). Turning to neoadjuvant therapy, Dr

-stage disease settings. After its initial FDA approval in 1998 for first-line treatment of HER2-positive metastatic breast cancer in combination with paclitaxel, a series of pivotal adjuvant studies documented statistically significant improvements in both

. Kelsey CR Chino JP Willett CG . Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancer . Int J Radiat Oncol Biol Phys 2007 ; 69 : 770 – 776 . 12. Javeri H Arora R Correa AM . Influence of induction

chemotherapy as per Keynote-407 (pembrolizumab, carboplatin and paclitaxel) due to continuous effusions, followed by protocol Keynote-189 (pembrolizumab, cisplatin, pemetrexed). Once his molecular testing revealed an EML4-ALK fusion, he was switched to oral